Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Trial details
- Registry ID
- NCT05696717
- Drugs studied
- Ampreloxetine
TrialRedline tracks 1 clinical trial sponsored by Theravance Biopharma: 1 Phase 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyNCT05696717 | Ampreloxetine | Active not recruiting | 2026-01Estimated |
Names as written in the registry records.